...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-Infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis
【24h】

Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-Infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis

机译:艾滋病毒感染的乌干达成年人结核病的结核分枝杆菌对磺胺甲恶唑的敏感性,采取甲氧苄啶-磺胺甲恶唑预防

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Additional drugs are needed for the treatment of multidrug-resistant tuberculosis (TB). Sulfamethoxazole has been shown to have in vitro activity against Mycobacterium tuberculosis; however, there is concern about resistance given the widespread use of trimethoprim-sulfamethoxazole prophylaxis among HIV-infected patients in sub-Saharan Africa. Thirty-eight of 40 Mycobacterium tuberculosis isolates (95%) from pretreatment sputum samples from Ugandan adults with pulmonary TB, including HIV-infected patients taking trimethoprim-sulfamethoxazole prophylaxis, were susceptible with MICs of <= 38.4 mu g/ml.
机译:治疗多药耐药结核病(TB)需要其他药物。磺胺甲基异恶唑已显示出对结核分枝杆菌具有体外活性。然而,由于在撒哈拉以南非洲的HIV感染患者中广泛使用甲氧苄啶-磺胺甲基异恶唑预防措施,人们对耐药性存在担忧。来自乌干达患有肺结核的成年人的预处理痰标本中的40株结核分枝杆菌中有38株(95%),包括接受甲氧苄啶-磺胺甲恶唑预防的HIV感染患者,其MIC≤38.4μg / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号